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multivariate analysis adjusted for disease aggressiveness, age 
and BMI. A TT> 10.4 nmol/l was associated with a hazard ratio of 
1.78 (95% CI 1.06-2.98, p = 0.03) for BCR. This difference in BCR 
appeared as a split on the Kaplan-Meier curve only five years 
after treatment. TT did not have an influence on overall survival 
(p = 0.28). 
Conclusions: Low baseline TT level is an independent prognostic 
factor associated with a lower BCR rate. This effect appears only 
five years after radiotherapy treatment. The results are to the 
contrary to what has been shown from patients treated with 
radical prostatectomy. 
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Purpose: Current clinical practice guidelines support the 
engagement of prostate cancer patients in their cancer care. 
However, the optimal timing of, and the most preferred sources 
of information provision and decision support desired by prostate 
cancer patients has not been systematically explored. In order 
to inform the design of strategies for information provision and 
decision support, we sought to determine prostate cancer 
patients’ preferences by conducting a systematic survey of 
recently diagnosed patients. 
Methods and Materials: Surveys were conducted in British 
Columbia, Alberta and Saskatchewan. Based on power 
calculations and estimated response rates, a random sample of 
prostate cancer patients in each provincial registry diagnosed in 
late 2012 was invited to participate. 
Results: Provincial response rates were 46%-55%, total n = 1007. 
Across provinces, mean age was 69 years. During the interval 
between diagnosis and the treatment decision, preferred 
information sources (not mutually exclusive) were the urologist 
(90%), family physician (85%), and radiation oncologists (58%). 
The Radiation Oncologist being identified as information source 
was highly dependent on whether the patient was managed with 
prostatectomy only (39%) versus primary radiotherapy (92%, p < 
0.01) whereas both groups identified the urologist as an 
important source (98% versus 94% respectively). Across all 
patients, 73% wanted printed information and 58% wanted 
information from the internet. Barriers to obtaining information 
from physicians included patients’ perception of physicians not 
having enough time (27%), worrying about physician time (21%), 
and worrying about asking too many questions (15%). Barriers to 
obtaining information from books and from the internet, 
respectively, included uncertain quality (37% and 46%, 
respectively), unclear if personally applicable (39% and 41%), and 
poor search skills (31% and 20%). Recommended facilitators for 
providing information included a person to guide its acquisition 
(71%), providing printed information (69%), and someone to 
answer questions: in person (77%), over the phone (53%), or via 
email (43%). Even if access was easy, 27% would not want 
information from the internet, and 13% would not want any 
printed information. Regarding decision making, 18% would have 
liked more help with their decision, though half of that group 
(53%) indicated that they felt well informed. 77% of all 
respondents either used decision support or would have wanted 
to if they had known about it. Recommended timing for decision 
support included before meeting any specialists (11%), at the 
urologist visit (31%), and after all specialist visits before the 
decision is made with a doctor (35%). 
Conclusions: Most prostate cancer patients want information 
and decision support but vary in where, when, and preferred 
medium. Optimal support needs to be multi-faceted and flexible. 
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Purpose: We previously identified circulating miRNA in 
metastatic prostate cancer patients that are associated with 
early castrate resistance (< 2 years). The current study 
determined whether the predictive miRNA were associated with 
time to castrate resistance (CRPC) in PSA recurrent and high-risk 
adjuvant patients. 
Methods and Materials: Patients from a prospective biomarker 
trial were categorized into three groups: 1) CRPC within two 
years of ADT, 2) CRPC greater than two years, and 3) patients 
remaining ADT sensitive. Total RNA was isolated from pre-
treatment plasma using the miRNeasy kit (Qiagen). For quality 
control, known concentrations of cel-miR-39 were added prior to 
RNA isolation. Isolated miRNA was subjected to reverse 
transcription (RT) using the miScript II RT Kit and primers specific 
to miRNA of interest. Quantification of individual miRNAs was 
performed by qPCR using the miScript SYBR Green PCR Kit and 
specific primers for miRNAs of interest following RT. 
Quantification of relative levels of miRNAs between samples was 
determined following comparison of the CT method of relative 
quantification following normalization to cel-miR-39 and the 
endogenous control SNORD61. 
Results: Previous work in metastatic patients identified 3 miRNA 
associated with development of early versus delayed CRPC. In 
the current study similar trends were observed for the third 
miRNA which was increased in early CRPC compared to other two 
groups. The second miRNA showed more variable expression 
amongst the three cohorts, and was generally lower in those 
patients who developed early CRPC. First miRNA was also lower 
in patients with early CRPC as compared other two groups, 
similar to our original findings in metastatic patients. 
Conclusions: A previously identified miRNA signature of early 
castrate resistance in metastatic patients appears to be 
applicable to PSA recurrent and high-risk patients. Future work 
will validate these findings in additional patients from our trial 
and independent cohorts. 
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Objectives: To assess the psychometric properties of a French 
Canadian version of the Expanded Prostate Cancer Index 
Composite Instrument (EPIC-50), among a clinical sample of 
prostate cancer patients. 
Methods and Materials: The validity of the French Canadian 
version of the EPIC-50 was assessed among patients from the 
radiation oncology and urology departments of CHU de Québec. 
A total of 251 patients were recruited. Participants taking part 
in the sensitivity to change study (n = 51) were asked to complete 
a battery of self-report scales at their consultation and at a 
follow up visit at the hospital, approximately six months after 
the initiation of their treatment. Another subsample of 68 
patients completed the EPIC on two occasions separated by two 
weeks to estimate temporal stability. The battery comprised the 
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